Amylin: What might be its role in alzheimer's disease and how could this affect therapy?

Expert Review of Proteomics

Volumn 10, Issue 5, 2013, Pages 403-405

  Despa, Florin ^a   Decarli, Charles ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; amylin; amyloid; cerebrovascular disease; dementia; hyperamylinemia; hyperinsulinemia; insulin resistance; obesity; type 2 diabetes

Indexed keywords

AMYLIN;

ALZHEIMER DISEASE; BRAIN INJURY; DEMENTIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; BRAIN; HUMANS; ISLET AMYLOID POLYPEPTIDE;

EID: 84886016804     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2013.841549     Document Type: Review

References (20)

1. Luchsinger JA. Type 2 diabetes and cognitive impairment: linking mechanisms. J. Alzheimers Dis. 30(0), S185-S198 (2012).
2. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 71(14), 1057-1064 (2008).
3. Nelson PT, Smith CD, Abner EA et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim. Biophys. Acta 1792(5), 454-469 (2009).
4. Arvanitakis Z, Schneider JA, Wilson RS et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67(11), 1960-1965 (2006).
5. Peila R, Rodriguez BL, Launer LJ; Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 51(4), 1256-1262 (2002).
6. Soininen H, Puranen M, Helkala EL, Laakso M, Riekkinen PJ. Diabetes mellitus and brain atrophy: a computed tomography study in an elderly population. Neurobiol. Aging. 13(6), 717-721 (1992).
7. den Heijer T, Venmeer SE, van Dijk EJ et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46(12), 1604-1610 (2003).
8. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 9(1), 35-66 (2012).
9. Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA 100(7), 4162-4167 (2003).
10. Sagare A, Deane R, Bell RD et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13(9), 1029-1031 (2007).
11. Alafuzoff I, Aho L, Helisalmi S,Mannermaa A, Soininen H. Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol. Appl. Neurobiol. 35(1) 60-68 (2009).
12. Craft S, Newcomer J, Kanne S et al. Memory improvement following induced hyperinsulinemia in alzheimer's disease. Neurobiol. Aging. 17(1), 123-130 (1996).
13. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 91(3), 795-826 (2011).
14. Gong W, Liu ZH, Zeng CH et al. Amylin deposition in the kidney of patients with diabetic nephropathy, Kidney Int. 72(2), 213-218 (2007).
15. Despa S, Margulies KB, Chen L et al. Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats. Circ. Res. 110(4), 598-608 (2012).
16. Jackson K, Barisone G, Jin L-W, DeCarli C, Despa F. Amylin deposition in the brain: a second amyloid in Alzheimer disease? Ann. Neurol. doi:10.1002/ana.23956 (2013) (Epub ahead of print).
17. Kawahara M, Kuroda Y, Arispe N, Rojas E. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J. Biol. Chem. 275(19), 14077-14083 (2000).
18. Collins JM, Despa F, Lee RC. Structural and functional recovery of electropermeabilized skeletal muscle in-vivo after treatment with surfactant poloxamer 188. Biochim. Biophys. Acta. 1768(5), 1238-1246 (2007).
19. Mina EW, Lasagna-Reeves C, Glabe CG, Kayed R. Poloxamer 188 copolymer membrane sealant rescues toxicity of amyloid oligomers in vitro. J. Mol. Biol. 3919(3) 577-585, (2009).
20. Lin C-Y, Gurlo T, Kayed R et al. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. Diabetes 56(5), 1324-1332 (2007).